MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 13, 2006; DOI: 10.1124/mol.106.030601


0026-895X/07/7103-884-892$20.00
Mol Pharmacol 71:884-892, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.030601v1
71/3/884    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimshoni, J. A.
Right arrow Articles by Bialer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimshoni, J. A.
Right arrow Articles by Bialer, M.

The Effects of Central Nervous System-Active Valproic Acid Constitutional Isomers, Cyclopropyl Analogs, and Amide Derivatives on Neuronal Growth Cone Behavior

J. A. Shimshoni, E. C. Dalton, A. Jenkins, S. Eyal, K. Ewan, R. S. B. Williams, N. Pessah, B. Yagen, A. J. Harwood, and M. Bialer

Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (J.A.S., S.E., N.P., M.B.); School of Biosciences, Cardiff University, Cardiff, United Kingdom (E.C.D., K.E., A.J.H.); Department of Biology, University College London, London, United Kingdom (A.J., R.S.B.W.); Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (B.Y.); and David R. Bloom Center for Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (B.Y., M.B.)

Valproic acid (VPA) is an effective antiepileptic drug with an additional activity for the treatment of bipolar disorder. It has been assumed that both activities arise from a common target. At the molecular level, VPA targets a number of distinct proteins that are involved in signal transduction. VPA inhibition of inositol synthase reduces the cellular concentration of myo-inositol, an effect common to the mood stabilizers lithium and carbamazepine. VPA inhibition of histone deacetylases activates Wnt signaling via elevated beta-catenin expression and causes teratogenicity. Given the VPA chemical structure, it may be possible to design VPA derivatives and analogs that modulate specific protein targets but leave the others unaffected. Indeed, it has been shown that some nonteratogenic VPA derivatives retain antiepileptic and inositol signaling effects. In this study, we describe a further set of VPA analogs and derivatives that separate anticonvulsant activity from effects on neuronal growth cone morphology. Lithium, carbamazepine, and VPA induce inositol-dependent spread of neuronal growth cones, providing a cell-based assay that correlates with mood-stabilizing activity. We find that two constitutional isomers of VPA, propylisopropylacetic acid and diisopropylacetic acid, but not their corresponding amides, and N-methyl-2,2,3,3-tetramethyl-cyclopropanecarboaxamide are more effective than VPA in increasing growth cone spreading. We show that these effects are associated with inositol depletion, and not changes in beta-catenin-mediated Wnt signaling. These results suggest a route to a new generation of central nervous system-active VPA analogs that specifically target bipolar disorder.


Received September 6, 2006; accepted December 13, 2006

Address correspondence to: Dr. Meir Bialer, Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Karem, P.O. Box 12065, Jerusalem 91120, Israel. E-mail: bialer{at}md.huji.ac.il




This article has been cited by other articles:


Home page
DMMHome page
J. S. King, R. Teo, J. Ryves, J. V. Reddy, O. Peters, B. Orabi, O. Hoeller, R. S. B. Williams, and A. J. Harwood
The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells
Dis. Model. Mech., May 1, 2009; 2(5-6): 306 - 312.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
X. Xu, A. Muller-Taubenberger, K. E. Adley, N. Pawolleck, V. W. Y. Lee, C. Wiedemann, T. S. Sihra, M. Maniak, T. Jin, and R. S. B. Williams
Attenuation of Phospholipid Signaling Provides a Novel Mechanism for the Action of Valproic Acid
Eukaryot. Cell, June 1, 2007; 6(6): 899 - 906.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics